Actithera
3 known investors
Actithera develops radioligand therapies (RLT) for cancer, using proprietary molecular design and chemistry to create compounds that concentrate in tumors while sparing healthy tissue. The company designs molecules that match radionuclide half-life with tumor residence time to enable effective treatment with fewer therapy cycles, with some compounds being prepared for clinical trials.
BiotechHealthtech
Founders & leadership
DD
Darshan DalalChief Medical Officer
Investors · 3
Frequently asked questions
- What does Actithera do?
- Actithera develops radioligand therapies (RLT) for cancer, using proprietary molecular design and chemistry to create compounds that concentrate in tumors while sparing healthy tissue. The company designs molecules that match radionuclide half-life with tumor residence time to enable effective treatment with fewer therapy cycles, with some compounds being prepared for clinical trials.
- Who are Actithera's investors?
- Actithera's investors include Hadean Ventures, M Ventures, Sofinnova Partners.